Empagliflozin (Jardiance) for Cardiorenal Protection in Patients with Reduced eGFR
Indications & Initiation Criteria
Dosing Recommendations
Pre‑Initiation Assessment
Monitoring & Follow‑Up
Safety‑Related Pitfalls (What to Avoid)
Evidence of Cardiovascular & Renal Benefit
Integration with Other CKD Therapies
Jardiance (Empagliflozin) GFR Thresholds for Cardiovascular and Renal Protection
Guideline-Based Approach
- The American Diabetes Association recommends SGLT2 inhibitors, including empagliflozin, can be used down to eGFR ≥20 mL/min/1.73 m² for reducing CKD progression and cardiovascular events in patients with diabetes 3, 4
- The American Diabetes Association suggests not using Jardiance for glucose lowering when eGFR <45 mL/min/1.73 m², as the glucose-lowering efficacy is significantly reduced due to its mechanism of action 4
Clinical Decision Algorithm
- For patients with eGFR 30-44 mL/min/1.73 m², the American Diabetes Association supports continuation of Jardiance for cardiovascular and renal protection if the patient has heart failure, established cardiovascular disease, or albuminuria 3, 4
- For patients with eGFR 20-29 mL/min/1.73 m², guidelines support continuation of Jardiance for cardiovascular and renal protection in patients already on therapy 3, 5